-
-
Overview
-
Clinic Signification:
In 2008, WHO separated “Myeloid/lymphoid neoplasms with eosinophilia associated with rearrangements of PDGFRA, PDGFRB, or FGFR1” into a new category. Even if the three abnormal target groups are not accompanied by BCR/ABL fusion genes, they are sensitive to imatinib treatment.Please contact us at for specific academic pricing.
-
- Properties
- Applications
-
Overview